VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Given Average Recommendation of “Reduce” by Analysts

Shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGN) have been assigned a consensus recommendation of “Reduce” from the five brokerages that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $0.95.

Several analysts have recently commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of VistaGen Therapeutics in a research report on Wednesday, June 3rd. Wall Street Zen lowered VistaGen Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st.

VistaGen Therapeutics Price Performance

Shares of VTGN stock traded up $0.01 during trading hours on Friday, reaching $0.26. 1,590,909 shares of the company traded hands, compared to its average volume of 4,516,474. The firm has a 50-day moving average price of $0.55 and a 200 day moving average price of $0.59. The company has a market cap of $10.59 million, a P/E ratio of -0.14 and a beta of 0.40. VistaGen Therapeutics has a 12-month low of $0.20 and a 12-month high of $5.14.

VistaGen Therapeutics (NASDAQ:VTGN) last released its earnings results on Monday, June 15th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). VistaGen Therapeutics had a negative return on equity of 133.02% and a negative net margin of 5,487.01%.The firm had revenue of $0.38 million for the quarter, compared to the consensus estimate of $0.40 million. During the same quarter in the previous year, the business posted ($1.67) EPS. Sell-side analysts predict that VistaGen Therapeutics will post -1.32 EPS for the current year.

Institutional Trading of VistaGen Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE lifted its holdings in VistaGen Therapeutics by 1,068.0% in the 4th quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock worth $62,000 after purchasing an additional 19,331 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in shares of VistaGen Therapeutics during the first quarter valued at approximately $25,000. Marshall Wace LLP purchased a new position in shares of VistaGen Therapeutics in the second quarter worth $69,000. Jane Street Group LLC bought a new position in shares of VistaGen Therapeutics during the second quarter worth $190,000. Finally, Dimensional Fund Advisors LP boosted its position in shares of VistaGen Therapeutics by 56.9% during the third quarter. Dimensional Fund Advisors LP now owns 68,017 shares of the company’s stock worth $241,000 after acquiring an additional 24,655 shares during the last quarter. Institutional investors own 78.39% of the company’s stock.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.